52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Akorn Provides Preliminary Third Quarter 2019 Results
Akorn Receives FDA Approval For Betamethasone Dipropionate Lotion USP
Akorn Receives FDA Approval For Azelastine Hydrochloride Nasal Spray
Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.
Biotechnology & Drugs
1925 W Field Ct Ste 300
Alan D. Weinstein
Independent Chairman of the Board
Douglas S. Boothe
President, Chief Executive Officer, Director
Duane A. Portwood
Chief Financial Officer, Executive Vice President
Joseph P. Bonaccorsi
Executive Vice President, General Counsel, Secretary
Executive Vice President of Global Quality
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
For securities litigators and deal lawyers, the consequences of two related appeals at the 7th U.S. Circuit Court of Appeals, both stemming from shareholder litigation over Akorn’s since-aborted merger with Fresenius Kabi AG, could be huge. The appeals court could provide...
The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The...
Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.
Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.
Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.
Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.
Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.
Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May, 2018.
Akorn Inc <AKRX.O> said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE <FREG.DE>.
The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest...
Germany's Fresenius SE <FREG.DE> won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc <AKRX.O>, sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.
A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.
Shares in German healthcare group Fresenius <FREG.DE> surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn <AKRX.O>.
The class action watchdogs at the Competitive Enterprise Institute lost a battle this week in their challenge to a $322,500 mootness fee for shareholders' lawyers who sued over Akorn Corporation’s M&A deal with Fresenius Kabi AG. U.S. District Judge Thomas Durkin of Chicago...
Fresenius SE's <FREG.DE> chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn <AKRX.O>, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.
Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.
German healthcare group Fresenius SE <FREG.DE> said on Thursday its legal battle with Akorn <AKRX.O> over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.
German healthcare group Fresenius <FREG.DE> alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc <AKRX.O> after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.
* DELAWARE COURT ORDERS AKORN-FRESENIUS TRIAL TO BEGIN JULY 9, WILL LAST ONE WEEK Further company coverage: (Reporting By Michael Erman)
German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.